Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962609 | 1.00 | GPR119 (0.55) | GPR119JAK2JAK1STSPRMT5 | |
| SCHEMBL25503496 | 0.84 | GPR119 (0.57) | GPR119JAK2JAK1STSPRMT5 | |
| SCHEMBL22284215 | 0.84 | GPR119 (0.54) | GPR119JAK2JAK1STSYAP1 | |
| SCHEMBL3580922 | 0.83 | GPR119 (0.56) | GPR119JAK2JAK1STSYAP1 | |
| SCHEMBL962183 | 0.82 | GPR119 (0.42) | GPR119PRMT5WDR77IDO1 | |
| SCHEMBL962181 | 0.82 | GPR119 (0.42) | GPR119PRMT5WDR77IDO1 | |
| SCHEMBL14121655 | 0.82 | GPR119 (0.42) | GPR119PRMT5WDR77IDO1 | |
| SCHEMBL27043883 | 0.82 | PRMT5 (0.62) | GPR119JAK2JAK1STSPRMT5 | |
| SCHEMBL22559199 | 0.81 | GPR119 (0.45) | GPR119JAK2JAK1STSPRMT5 | |
| SCHEMBL14406041 | 0.80 | KDM4E (0.53) | GPR119JAK2JAK1STSPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853255-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2456436-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8637568-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637568-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637568-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8501964-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501964-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501964-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8455665-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273786-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2012075239-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | GPR119 1219/4885JAK2 428/4885JAK1 1130/4885 |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | GPR119 619/4885JAK2 699/4885JAK1 576/4885 |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | GPR119 619/4885JAK2 699/4885JAK1 576/4885 |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | GPR119 1219/4885JAK2 428/4885JAK1 1130/4885 |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | GPR119 1219/4885JAK2 428/4885JAK1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.